GENERAL, O. Reg. 201/96

Section 1

Cite as GENERAL, O. Reg. 201/96, s. 1 · current to November 11, 2026 · consolidated from July 1, 2026 · read from e-Laws on November 16, 2026

The text

(1) In this Regulation, “biologic drug product” means a drug derived from living organisms or their cells; (“produit médicamenteux biologique”) “biosimilar product” means a biologic drug product that has been approved for sale in Canada by Health Canada based on information comparing the biosimilar product to an original biologic product; (“produit biosimilaire”) “drug cost amount” means the quantity of a drug product multiplied by the drug benefit price of the drug product; (“coût indiqué du médicament”) “extemporaneous preparation” means a drug or combination of drugs prepared or compounded in a pharmacy according to a prescription; (“médicament préparé extemporanément”) “generic line extension drug product” means a drug product with the same active ingredient or ingredients in the same or similar dosage form as an original product, but in a strength for which no original product exists; (“produit médicamenteux générique comportant une extension de gamme”) “Ministry” means the Ministry of Health and Long-Term Care; (“ministère”) “modified release dosage form” means a dosage form of a product that is formulated to control the level of the drug in the blood over a shorter or longer period of time than a conventional dosage form; (“forme posologique à libération modifiée”) “original biologic product” means the original source of a biologic drug product in a particular strength and dosage form; (“produit biologique d’origine”) “original product” means the original source of a drug product in a particular strength and dosage form; (“produit d’origine”) “section 20.2 maximum co-payment” means the maximum co-payment determined in accordance with the rules set out in subsection 20.2 (4); (“quote-part maximale prévue à l’article 20.2”) “spouse” means a person, (a) to whom the person is married, or (b) with whom the person is living in a conjugal relationship outside marriage, if the two persons, (i) have cohabited for at least one year, (ii) are together the parents of a child, or (iii) have together entered into a cohabitation agreement under section 53 of the Family Law Act; (“conjoint”) “unit” means a gram, millilitre, tablet, capsule or other appropriate unit of a listed drug product in a particular dosage form and strength. (“unité”) O. Reg. 201/96, s. 1; O. Reg. 324/96, s. 1; O. Reg. 336/96, s. 1; O. Reg. 375/96, s. 1; O. Reg. 508/96, s. 1 (1); O. Reg. 110/97, s. 1; O. Reg. 299/97, s. 1; O. Reg. 612/98, s. 1; O. Reg. 72/99, s. 1; O. Reg. 332/99, s. 1; O. Reg. 401/99, s. 1; O. Reg. 588/99, s. 1; O. Reg. 69/00, s. 1; O. Reg. 202/00, s. 1 (1); O. Reg. 366/00, s. 1; O. Reg. 584/00, s. 1; O. Reg. 16/01, s. 1; O. Reg. 172/01, s. 1 (1); O. Reg. 358/01, s. 1; O. Reg. 64/02, s. 1; O. Reg. 214/02, s. 1; O. Reg. 395/02, s. 1; O. Reg. 88/03, s. 1; O. Reg. 334/03, s. 1; O. Reg. 60/04, s. 1; O. Reg. 184/04, s. 1; O. Reg. 321/04, s. 1; O. Reg. 12/05, s. 1; O. Reg. 191/05, s. 1; O. Reg. 334/05, s. 1; O. Reg. 484/05, s. 1 (1); O. Reg. 645/05, s. 1 (1); O. Reg. 55/06, s. 1 (1); O. Reg. 202/06, s. 1; O. Reg. 459/06, s. 1 (1, 2); O. Reg. 320/07, s. 1; O. Reg. 436/19, s. 1; O. Reg. 211/20, s. 1; O. Reg. 97/26, s. 1. (1.1) The functions and powers of the executive officer set out in subsection 1.1 (2) of the Act include the power, (a) to hold competitions for the purpose of selecting drug products that may be listed or continue to be listed as designated drug products on the Formulary or for any other purpose under the Act; (b) to use the results of such competitions in exercising any of the executive officer’s powers under the Act, including designating or continuing to designate a drug product as a listed drug product under section 19 of the Act or removing such a designation under section 20 of the Act; and (c) to enter into agreements that contain, among other things, provisions with respect to volume discounts and payments to the Minister of Finance. O. Reg. 356/08, s. 1. (1.2) The executive officer shall not, under section 16 of the Act, make the Act apply in respect of a drug that is a drug product described in subsection 12 (9) of this Regulation, unless the conditions set out in that subsection are met. O. Reg. 20/13, s. 1. (2) For the purposes of subsection 1 (2) of the Act, “therapeutic substitution” means the substitution of a drug that contains chemically different active ingredients that are considered to be therapeutically equivalent, without authorization from a person authorized to prescribe drugs within the scope of his or her practice of a health profession. O. Reg. 459/06, s. 1 (3). (3) The executive officer may enter into agreements for the purposes of carrying out his or her functions under clause 1.1 (2) (a) of the Act. O. Reg. 459/06, s. 1 (3). (4) The executive officer may, in writing, delegate his or her authority under clause 1.1 (2) (c), (f) or (g) of the Act or subsection 1 (3) of this Regulation to any person employed in the Ministry. O. Reg. 459/06, s. 1 (3). (5) For greater clarity, the power of the executive officer under clause 1.1 (2) (f) of the Act to negotiate agreements includes the power to enter into such agreements that have been negotiated. O. Reg. 459/06, s. 1 (3). (6) Revoked: O. Reg. 220/10, s. 1 (2). (7) Revoked: O. Reg. 797/21, s. 1. (8) For greater certainty, a benefit provided as a professional allowance before July 1, 2010 is a rebate and is not a professional allowance unless the manufacturer providing the benefit and the person receiving it report to the executive officer the amount of professional allowance paid or received in the same manner as provided in Schedule 3 of this Regulation as it read before July 1, 2010. O. Reg. 220/10, s. 1 (3). (9), (10) Revoked: O. Reg. 220/10, s. 1 (3). (11) For the purposes of section 11.5 of the Act, a “rebate” does not include the value of a benefit that is provided in accordance with ordinary commercial terms that meet all of the following conditions: 1. The benefit is provided in the ordinary course of business in the supply chain system of listed drug products that are designated as interchangeable under the Drug Interchangeability and Dispensing Fee Act between any of a manufacturer, a wholesaler, an operator of a pharmacy or a company that owns, operates or franchises pharmacies. 2. The value of the benefit is set out in a written agreement between any of a manufacturer, a wholesaler, an operator of a pharmacy and a company that owns, operates or franchises pharmacies. 3. The benefit relates to an ordinary commercial relationship that is any of the following: i. A prompt payment discount. ii. A volume discount. iii. A distribution service fee. 4. Revoked: O. Reg. 434/19, s. 1. 5. A person who receives the benefit reports to the executive officer, if required by the executive officer to do so, the net selling price of the drug products representing the drug benefit price less the value of the benefits received. O. Reg. 220/10, s. 1 (4); O. Reg. 434/19, s. 1. (12) For the purposes of section 11.5 of the Act, a “rebate” does not include the value of a benefit provided in accordance with ordinary commercial terms with respect to a listed drug product that is not interchangeable where the ordinary commercial terms are a discount for prompt payment. O. Reg. 220/10, s. 1 (4).
Read the GENERAL on e-Laws ↗

Made under Ontario Drug Benefit Act, R.S.O. 1990, c. O.10.